MX2011013258A - Proteinas de fusion para entrega de gdnf y bdnf al sistema nervioso central. - Google Patents
Proteinas de fusion para entrega de gdnf y bdnf al sistema nervioso central.Info
- Publication number
- MX2011013258A MX2011013258A MX2011013258A MX2011013258A MX2011013258A MX 2011013258 A MX2011013258 A MX 2011013258A MX 2011013258 A MX2011013258 A MX 2011013258A MX 2011013258 A MX2011013258 A MX 2011013258A MX 2011013258 A MX2011013258 A MX 2011013258A
- Authority
- MX
- Mexico
- Prior art keywords
- gdnf
- bdnf
- delivery
- nervous system
- fusion proteins
- Prior art date
Links
- 101150035467 BDNF gene Proteins 0.000 title 1
- 210000003169 central nervous system Anatomy 0.000 title 1
- 102000037865 fusion proteins Human genes 0.000 title 1
- 108020001507 fusion proteins Proteins 0.000 title 1
- 101150082979 gdnf gene Proteins 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 102000004219 Brain-derived neurotrophic factor Human genes 0.000 abstract 2
- 108090000715 Brain-derived neurotrophic factor Proteins 0.000 abstract 2
- 102000034615 Glial cell line-derived neurotrophic factor Human genes 0.000 abstract 2
- 108091010837 Glial cell line-derived neurotrophic factor Proteins 0.000 abstract 2
- 229940077737 brain-derived neurotrophic factor Drugs 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 108010064942 Angiopep-2 Proteins 0.000 abstract 1
- 208000020401 Depressive disease Diseases 0.000 abstract 1
- 208000018737 Parkinson disease Diseases 0.000 abstract 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 abstract 1
- 230000008499 blood brain barrier function Effects 0.000 abstract 1
- 210000001218 blood-brain barrier Anatomy 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 230000004770 neurodegeneration Effects 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
- 230000007514 neuronal growth Effects 0.000 abstract 1
- 230000006576 neuronal survival Effects 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 201000000980 schizophrenia Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/4756—Neuregulins, i.e. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/48—Nerve growth factor [NGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Veterinary Medicine (AREA)
- Neurosurgery (AREA)
- Public Health (AREA)
- Neurology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US18624609P | 2009-06-11 | 2009-06-11 | |
| PCT/CA2010/000889 WO2010142035A1 (en) | 2009-06-11 | 2010-06-11 | Fusion proteins for delivery of gdnf and bdnf to the central nervous system |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2011013258A true MX2011013258A (es) | 2012-02-28 |
Family
ID=43308346
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2011013258A MX2011013258A (es) | 2009-06-11 | 2010-06-11 | Proteinas de fusion para entrega de gdnf y bdnf al sistema nervioso central. |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20120196803A1 (enExample) |
| EP (1) | EP2440581A4 (enExample) |
| JP (1) | JP2012529272A (enExample) |
| CN (2) | CN103819564A (enExample) |
| AU (1) | AU2010258052A1 (enExample) |
| BR (1) | BRPI1012971A2 (enExample) |
| CA (1) | CA2764777A1 (enExample) |
| MX (1) | MX2011013258A (enExample) |
| WO (1) | WO2010142035A1 (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4903036B2 (ja) | 2003-01-06 | 2012-03-21 | アンジオケム・インコーポレーテッド | 血液脳関門を通過する担体としてのアプロチニンおよび類似体 |
| WO2007009229A1 (en) | 2005-07-15 | 2007-01-25 | Angiochem Inc. | Use of aprotinin polypeptides as carriers in pharmaceutical conjugates |
| EP2074142A4 (en) | 2006-10-19 | 2010-10-27 | Angiochem Inc | COMPOUNDS FOR STIMULATING THE FUNCTION OF P-GLYCOPROTEIN AND APPLICATIONS THEREOF |
| US9365634B2 (en) | 2007-05-29 | 2016-06-14 | Angiochem Inc. | Aprotinin-like polypeptides for delivering agents conjugated thereto to tissues |
| WO2010043047A1 (en) | 2008-10-15 | 2010-04-22 | Angiochem Inc. | Conjugates of glp-1 agonists and uses thereof |
| US9914754B2 (en) | 2008-12-05 | 2018-03-13 | Angiochem Inc. | Conjugates of neurotensin or neurotensin analogs and uses thereof |
| AU2009327267A1 (en) | 2008-12-17 | 2011-07-14 | Angiochem, Inc. | Membrane type-1 matrix metalloprotein inhibitors and uses thereof |
| ES2729261T3 (es) | 2009-04-20 | 2019-10-31 | Angiochem Inc | Tratamiento del cáncer de ovario utilizando un agente anticancerígeno conjugado con un análogo de Angiopep-2 |
| WO2011000095A1 (en) | 2009-07-02 | 2011-01-06 | Angiochem Inc. | Multimeric peptide conjugates and uses thereof |
| WO2011153642A1 (en) * | 2010-06-10 | 2011-12-15 | Angiochem Inc. | Leptin and leptin analog conjugates and fusion proteins and uses thereof |
| MX2013000250A (es) * | 2010-07-02 | 2013-10-28 | Angiochem Inc | Polipeptidos cortos y que contienen d-aminoacido para conjugados terapeuticos y usos de los mismos. |
| JP2015526434A (ja) | 2012-08-14 | 2015-09-10 | アンジオケム インコーポレーテッド | ペプチド−デンドリマーコンジュゲート及びその使用 |
| JP6234331B2 (ja) * | 2014-06-13 | 2017-11-22 | 森永乳業株式会社 | 統合失調症治療剤 |
| EP3307326B9 (en) | 2015-06-15 | 2021-02-24 | Angiochem Inc. | Methods for the treatment of leptomeningeal carcinomatosis |
| JP7000349B2 (ja) | 2016-05-13 | 2022-02-04 | インスティテュート デ メディシナ モレキュラー ジョアオ ロボ アントゥネス | Ｉｌｃ３細胞に関連する疾患を処置する方法 |
| AU2017357931B2 (en) | 2016-11-10 | 2024-12-05 | Keros Therapeutics, Inc. | GDNF fusion polypeptides and methods of use thereof |
| CN107141354A (zh) * | 2017-05-05 | 2017-09-08 | 李斯文 | 一种融合蛋白及光敏剂复合物及其制备方法和应用 |
| WO2021015584A1 (ko) * | 2019-07-24 | 2021-01-28 | 주식회사 에스엘바이젠 | 불사화된 줄기세포주의 제조 방법 및 이의 용도 |
| JP2024522938A (ja) | 2021-06-03 | 2024-06-21 | フンダサン デー．アンナ ジ ソーメル チャンパリマウド エー ドクトル カルロス モンテス チャンパリマウド | 脳－脂肪回路を介してｉｌｃ２および肥満度を制御する神経－間葉単位 |
| CN116270429B (zh) * | 2023-02-17 | 2025-06-10 | 山东省药学科学院 | 一种鼻黏膜给药的抗抑郁制剂及其制备方法和应用 |
| CN120077136A (zh) * | 2023-09-28 | 2025-05-30 | 广州必贝特医药股份有限公司 | 抑制淀粉样前体蛋白（APP）基因表达的siRNA、药物及其应用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0520032A2 (pt) * | 2005-02-18 | 2009-04-14 | Angiochem Inc | moléculas para transportar um composto através da barreira hematoencefálica |
| US20090016959A1 (en) * | 2005-02-18 | 2009-01-15 | Richard Beliveau | Delivery of antibodies to the central nervous system |
| US8142781B2 (en) * | 2005-10-07 | 2012-03-27 | Armagen Technologies, Inc. | Fusion proteins for blood-brain barrier delivery |
| AU2008255556B2 (en) * | 2007-05-29 | 2014-08-07 | Angiochem, Inc. | Aprotinin-like polypeptides for delivering agents conjugated thereto to tissues |
| US8802631B2 (en) * | 2007-09-17 | 2014-08-12 | Ludwig Institute For Cancer Research Ltd. | Peptides and methods for the treatment of gliomas and other cancers |
| WO2009070597A2 (en) * | 2007-11-26 | 2009-06-04 | Armagen Technologies, Inc. | Fusion proteins for delivery of gdnf to the cns |
-
2010
- 2010-06-11 CA CA2764777A patent/CA2764777A1/en not_active Abandoned
- 2010-06-11 MX MX2011013258A patent/MX2011013258A/es not_active Application Discontinuation
- 2010-06-11 WO PCT/CA2010/000889 patent/WO2010142035A1/en not_active Ceased
- 2010-06-11 BR BRPI1012971A patent/BRPI1012971A2/pt not_active IP Right Cessation
- 2010-06-11 JP JP2012514307A patent/JP2012529272A/ja active Pending
- 2010-06-11 US US13/377,480 patent/US20120196803A1/en not_active Abandoned
- 2010-06-11 EP EP10785633A patent/EP2440581A4/en not_active Withdrawn
- 2010-06-11 CN CN201410030902.XA patent/CN103819564A/zh active Pending
- 2010-06-11 CN CN2010800317596A patent/CN102459348A/zh active Pending
- 2010-06-11 AU AU2010258052A patent/AU2010258052A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP2440581A4 (en) | 2013-03-27 |
| CA2764777A1 (en) | 2010-12-16 |
| AU2010258052A1 (en) | 2012-01-12 |
| US20120196803A1 (en) | 2012-08-02 |
| WO2010142035A1 (en) | 2010-12-16 |
| BRPI1012971A2 (pt) | 2018-01-16 |
| EP2440581A1 (en) | 2012-04-18 |
| CN102459348A (zh) | 2012-05-16 |
| JP2012529272A (ja) | 2012-11-22 |
| CN103819564A (zh) | 2014-05-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2011013258A (es) | Proteinas de fusion para entrega de gdnf y bdnf al sistema nervioso central. | |
| WO2012142320A8 (en) | Compositions and methods for preventing or treating diseases, conditions, or processes characterized by aberrant fibroblast proliferation and extracellular matrix deposition | |
| SA520411820B1 (ar) | تراكيب من ببتيدات تاو مفسفرة واستخداماتها | |
| BR0307819A (pt) | Derivados de pirazol tricìclicos, processo para preparação dos mesmos como agentes antitumorais | |
| TNSN07238A1 (en) | Method for producing sterile suspensions or lyophilisates of poorly soluble basic peptide complexes. pharmaceutical formulations containing the same, and use thereof as medicaments | |
| CL2010001467A1 (es) | Compuestos derivados de fenil-imidazol sustituido con un heteroaromatico biciclico; composicion farmaceutica que los comprende; y su uso como inhibidores de la pde10a para tratar trastornos neurodegenerativos o psiquiatricos como alzheimer, demencia alcoholica, trastorno del aprendizaje, esquizofrenia, adiccion a las drogas. | |
| EA201991375A1 (ru) | Бицикло[1.1.1]пентановые ингибиторы киназы, содержащей домен с двумя лейциновыми "застежками-молниями" (dlk), для лечения заболевания | |
| EP4083058A3 (en) | Delivery constructs for transcytosis and related methods | |
| MX2010006211A (es) | Proteínas elastasa recombinantes y métodos de fabricación y uso de las mismas. | |
| MXPA05012391A (es) | Tratamiento de trastornos psicoticos y depresivos. | |
| BR112019004243A2 (pt) | composto, composição farmacêutica, método para inibição de quinase do zíper de leucina dupla, método para tratamento de uma doença mediada por quinase do zíper de leucina dupla e método para obter um efeito em um paciente | |
| ATE457985T1 (de) | Substituierte pyrazinonderivate zur verwendung als arzneimittel | |
| MX2011012677A (es) | Conjugados de albumina-peptido amiloide y usos de los mismos. | |
| PT1778837E (pt) | Tratamento de doenças neurodegenerativas por utilização de inibidores de scd4 | |
| ATE524487T1 (de) | Tau peptidmimetikum zur behandlung von neurodegenerativen erkrankungen | |
| EP1969003B8 (en) | Uses of a NEUROTROPHIC FACTOR PROTEIN | |
| MX2017002476A (es) | Composiciones y metodos para prevenir o tratar enfermedades, condiciones o procesos caracterizados por proliferacion de fibroblasto aberrante y matriz extracelular. | |
| MX2010008706A (es) | Derivados de fenil-prenilo, de origen marino y sintetico. para el tratamiento de enfermedades o trastornos cognitivos, neurodegenerativos o neuronales. | |
| Adachi et al. | Potent and selective oxytocin receptor agonists without disulfide bridges | |
| WO2022204362A3 (en) | Compositions and methods for treating a neurodegenerative or developmental disorder | |
| ZA200700945B (en) | Derivatives of 1-phenylalkanecarboxylic acids for the treatment of neurodegenerative diseases | |
| ATE471322T1 (de) | Substituierte pyrazinonderivate zur verwendung als arzneimittel | |
| EP1958939A3 (en) | Pyrazole-amine compounds for the treatment of neurodegenerative disorders | |
| SI2123328T1 (sl) | Galantaminski derivati, postopki za njihovo pridobivanje in uporabo | |
| UA94615C2 (uk) | Інгібітори транспортера-1 гліцину |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |